Aytu Biopharma Inc AYTU

$2.07 -0.02 (-0.96%)

Valuation

Market cap
22,712,000
Revenue TTM
$57,570,000
Net income TTM
$-14,250,000
PE ratio
0.00
Forward PE
8.56
Profit margin
-24.75%
Debt to equity
0.48

Trading

Volume
15,800
Avg volume
38,716
Day's range
$2.06 – $2.15
Shares out
10,867,000
Stochastic %K
10%
Beta
0.17
Analysts
Strong Sell
Price target
$9.67

Price

Company profile

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indi...

Show more

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
720 437 6580
Website
https://aytubio.com
Address
7900 East Union Avenue, Suite 920, Denver, United States

Latest news